Jeffrey R.
Strich, MD, MHS
CDR, USPHS
Lasker Clinical Research Scholar
Tenure Track Investigator
Chief, Laboratory of Critical Illness Pathogenesis and Therapeutics
301-496-9320
Dr. Jeffrey Strich leads the Laboratory of Critical Illness Pathogenesis and Therapeutics which focuses on understanding the pathogenesis and developing novel host-directed therapies targeting the dysregulated innate immune response that occurs during infections that cause critical illness.
MD, Uniformed Services University of the Health Sciences
MHS, Duke University School of Medicine
MS, University of Connecticut
Dr. Strich received his undergraduate degree from the University of Connecticut in Molecular and Cell Biology, his degree in Medicine from the Uniformed Services University of the Health Sciences, and his Masters in Health Services in Clinical Research from the Duke University School of Medicine. He completed residency training in Internal Medicine at Georgetown University Hospital and then completed a combined fellowship in Critical Care Medicine and Infectious Diseases at the National Institutes of Health.
Dr. Strich is a Medical Officer in the United States Public Health Services Commissioned Corps. Prior to pursuing his degree in Medicine he served as a Special Assistant in the Office of the Surgeon General. Dr. Strich is a member of the Infectious Disease Society of America (IDSA) the Society of Critical Care Medicine, and serves on the editorial board of Critical Care Explorations. He holds an appointment as an Adjunct Assistant Professor of Medicine at the Uniformed Services University of the Health Sciences.
Dr. Strich’s research interests are focused on developing therapies for and understanding the role of the innate immune system in infections that cause critical illness through human clinical trials, large animal models and ex vivo translational studies with a particular focus on bacterial sepsis and SARS-CoV-2 infection. Dr. Strich is particularly interested in studying the contribution and therapeutics targeting low-density neutrophils (LDNs), a subset of neutrophils traditionally identified in the peripheral blood mononuclear cell (PBMC) fraction of gradient density separation.
- NHLBI Directors Award: For developing an innovation model of bacterial sepsis and identifying spleen tyrosine kinase as a potential novel sepsis therapeutic, 2024
- NHLBI Directors Award: For conducting six high-quality, heavily cited studies on COVID19 epidemiology in one year – using near-real-time-data – which have provided valuable insights into improving health care delivery and minimizing excess deaths during pandemics, 2024
- PHS Outstanding Unit Commendation, 2022
- PHS Crisis Response Service Medal, 2021 and 2022
- NIH Directors Award, 2021
- NHLBI Directors Award, 2021
- USPHS Presidential Unit Citation, 2021
- NIH Clinical Center CEO Award, 2021
- NIH Clinical Center CEO Award, 2020
- USPHS PHS Achievement Medal, 2020
- USPHS Unit commendation, 2020
- USPHS Commendation Medal, 2020
- USPHS Commendation Medal, 2019
- USPHS Unit commendation, 2019
- NIH Clinical Center CEO Award, 2018
- USPHS Presidential Unit Citation, 2016
- Eric Lemmer Memorial Research Award, 2015
- USPHS PHS Achievement Medal, 2013
- USPHS PHS Citation, 2010
- USPHS PHS Citation, 2008
- USPHS PHS Unit Commendation, 2008
- Department of Defense Global War on Terrorism Medal, 2008
- Department of Defense National Defense Service Medal, 2008
R406 reduces lipopolysaccharide-induced neutrophil activation. Warner S, Teague HL, Ramos-Benitez MJ, Panicker S, Allen K, Gairhe S, Moyer T, Parachalil Gopalan B, Douagi I, Shet A, Kanthi Y, Suffredini AF, Chertow DS, Strich JR. Cell Immunol. 2024 Sep-Oct;403-404:104860. doi: 10.1016/j.cellimm.2024.104860. Epub 2024 Jul 26. PMID: 39084187
Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19. Wigerblad G, Warner SA, Ramos-Benitez MJ, Kardava L, Tian X, Miao R, Reger R, Chakraborty M, Wong S, Kanthi Y, Suffredini AF, Dell'Orso S, Brooks S, King C, Shlobin O, Nathan SD, Cohen J, Moir S, Childs RW, Kaplan MJ, Chertow DS, Strich JR. Sci Adv. 2023 Jan 4;9(1):eade8272. doi: 10.1126/sciadv.ade8272. Epub 2023 Jan 4. PMID: 36598976
Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial. Strich JR, Tian X, Samour M, King CS, Shlobin O, Reger R, Cohen J, Ahmad K, Brown AW, Khangoora V, Aryal S, Migdady Y, Kyte JJ, Joo J, Hays R, Collins AC, Battle E, Valdez J, Rivero J, Kim IH, Erb-Alvarez J, Shalhoub R, Chakraborty M, Wong S, Colton B, Ramos-Benitez MJ, Warner S, Chertow DS, Olivier KN, Aue G, Davey RT, Suffredini AF, Childs RW, Nathan SD. Clin Infect Dis. 2022 Aug 24;75(1):e491-e498. doi: 10.1093/cid/ciab732. PMID: 34467402
Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. Strich JR, Ramos-Benitez MJ, Randazzo D, Stein SR, Babyak A, Davey RT, Suffredini AF, Childs RW, Chertow DS. J Infect Dis. 2021 Mar 29;223(6):981-984. doi: 10.1093/infdis/jiaa789. PMID: 33367731
Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study. Strich JR, Mishuk A, Diao G, Lawandi A, Li W, Demirkale CY, Babiker A, Mancera A, Swihart BJ, Walker M, Yek C, Neupane M, De Jonge N, Warner S, Kadri SS; National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative. Ann Intern Med. 2024 May;177(5):559-572. doi: 10.7326/M23-2309. Epub 2024 Apr 19. PMID: 38639548
Visit PubMed.gov for a full list of Dr. Strich's publications.